Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 18, Issue 2, 2012, Pages 487-498

  Tromp, Jacqueline M ^a   Geest, Christian R ^a   Breij, Esther C W ^a   Elias, Judith A ^a   Van Laar, Jacoline ^a   Luijks, Dieuwertje M ^a   Kater, Arnon P ^a   Beaumont, Tim ^a   Van Oers, Marinus H J ^a   Eldering, Eric ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTILEUKEMIC AGENT; BORTEZOMIB; CD40 LIGAND; DASATINIB; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN NOXA; ROSCOVITINE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL IMMORTALIZATION; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; CD40 LIGAND; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH NODES; MICE; MIDDLE AGED; NF-KAPPA B; NIH 3T3 CELLS; NITROPHENOLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; SIGNAL TRANSDUCTION; SULFONAMIDES; THIAZOLES; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 84855992825     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1440     Document Type: Article

References (38)

1. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85: 1580-9.
2. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 2007;21:1885-91. (Pubitemid 47299960)
3. Zenz T, Benner A, Dohner H, Stilgenbauer S. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 2008;7:3810-4.
4. Burger JA, Gandhi V. The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood 2009;114:2560-1.
5. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003;123:380-8. (Pubitemid 37363477)
6. Munk PI, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004;45:2365-72. (Pubitemid 40081179)
7. Smit LA, Hallaert DY, Spijker R, de Goeij B, Jaspers A, Kater AP, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007;109:1660-8. (Pubitemid 46242110)
8. Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP, et al. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010;29:5071-82.
9. Hallaert DY, Jaspers A, van Noesel CJ, van Oers MH, Kater AP, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008;112:5141-9.
10. Kater AP, Evers LM, Remmerswaal EB, Jaspers A, Oosterwijk MF, van Lier RA, et al. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004;127:404-15. (Pubitemid 39536592)
11. Willimott S, Baou M, Naresh K, Wagner SD. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br J Haematol 2007;138:721-32. (Pubitemid 47313210)
12. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998;92: 990-5. (Pubitemid 28355483)
13. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81. (Pubitemid 40825512)
14. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10: 375-88. (Pubitemid 44693472)
15. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-91. (Pubitemid 46192219)
16. Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C, et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combinationwith histone deacetylase inhibitors. Blood 2009;113:1982-91.
17. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010;115:3304-13.
18. Weber A, Kirejczyk Z, Potthoff S, Ploner C, Hacker G. Endogenous Noxa determines the strong proapoptotic synergism of the BH3- mimetic ABT-737 with chemotherapeutic agents in human melanoma cells. Transl Oncol 2009;2:73-83.
19. Zall H, Weber A, Besch R, Zantl N, Hacker G. Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1. Mol Cancer 2010;9:164.
20. Okumura K, Huang S, Sinicrope FA. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res 2008;14:8132-42.
21. Hagenbuchner J, Ausserlechner MJ, Porto V, David R, Meister B, Bodner M, et al. The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression. J Biol Chem 2010;285:6904-12.
22. Hauck P, Chao BH, Litz J, Krystal GW. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther 2009;8:883-92.
23. Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol 2009;75:1231-9.
24. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403. (Pubitemid 40193310)
25. Hallaert DY, Spijker R, Jak M, Derks IA, Alves NL, Wensveen FM, et al. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. Cell Death Differ 2007;14:1958-67. (Pubitemid 350011671)
26. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, et al. Concurrent upregulation of BCL-XL and BCL2A1 induces∼1000- fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009;113:4403-13.
27. Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD, et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009;23:2034-41.
28. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84:1415-20. (Pubitemid 24273007)
29. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, Lukens MV, et al. Generation of stablemonoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 2010;16:123-8.
30. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk I, Hahlen K, van Wering ER. Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res 1995;19:175-81.
31. Tonino SH, van Gelder M, Eldering E, van Oers MH, Kater AP. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. Leukemia 2010;24:652-4.
32. Del GMV, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.J Clin Invest 2007;117:112-21. (Pubitemid 46048458)
33. Lioni M, Noma K, Snyder A, Klein-Szanto A, Diehl JA, Rustgi AK, et al. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol Cancer Ther 2008;7:2866-75.
34. Hassan M, Alaoui A, Feyen O, Mirmohammadsadegh A, Essmann F, Tannapfel A, et al. The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways. Oncogene 2008; 27:4557-68.
35. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-99.
36. Cuadrado A, Lafarga V, Cheung PC, Dolado I, Llanos S, Cohen P, et al. A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis. EMBO J 2007;26:2115-26. (Pubitemid 46625792)
37. Scielzo C, Apollonio B, Scarfo L, Janus A, Muzio M, Ten Hacken E, et al. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia 2011;25:1760-7.
38. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-{kappa}B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-74.